Eurofins has launched a new CE marked serological assay, the GSD NovaLisa SARS-CoV-2 (Covid-19) quantitative IgG, for identifying and measuring the level of antibodies to the SARS-CoV-2 virus. This ELISA kit detects antibodies raised by an infection or vaccination. The launch is expected to support vaccination campaigns by confirming the immune response to the virus and vaccines over time.
Proterixbio has sought commercial availability of a quantitative Covid-19 serology assay validated for dried blood spots (DBS) from a finger stick. An update from the SARS-CoV-2 (RBD) IgG antibody test, the assay is a testing service being offered through the company’s high-complexity Clinical Laboratory Improvement Amendments of 1988 (CLIA) testing laboratory.
Cue Health, a medical diagnostic products manufacturer, announced results from a Mayo Clinic Laboratories’ clinical validation study, which evaluated the accuracy of Cue’s Covid-19 test in point-of-care settings against the centralised lab PCR testing model. The study included 292 patient samples at a Mayo Clinic collection site. The study found that the overall agreement between the Cue point-of-care test and the reference laboratory tests was 97.8%.
BioIQ, a healthcare engagement and quality care gap closure company, and Biomeme, a real-time PCR testing solutions provider, have collaborated to bring Biomeme’s mobile RT-PCR Covid-19 test to BioIQ’s Covid testing platform and on-site testing events. The move aims to eliminate latency associated with sending samples away and false negatives/false positives associated with less sensitive, lower accuracy molecular and antigen tests.